provides general information regarding cytisine

Quit Smoking with Tabex
Sopharma Shop


This domain name (or website with content) is available for sale by its owner.

Any offer you submit is binding for 7 days.

If you require futher information contact us.


Please enable JavaScript in your browser to complete this form.

Achieve Life Sciences (NASDAQ:ACHVGet Rating)‘s stock had its “outperform” rating reissued by equities research analysts at Oppenheimer in a research report issued on Friday, Benzinga reports. They currently have a $17.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price objective would indicate a potential upside of 290.80% from the stock’s current price.

Achieve Life Sciences Price Performance

Shares of ACHV stock opened at $4.35 on Friday. The stock has a 50 day moving average price of $4.83 and a 200 day moving average price of $3.62. Achieve Life Sciences has a 52-week low of $2.00 and a 52-week high of $8.13. The company has a debt-to-equity ratio of 15.10, a quick ratio of 3.03 and a current ratio of 3.03. The firm has a market capitalization of $77.87 million, a P/E ratio of -1.09 and a beta of 1.44.

Achieve Life Sciences (NASDAQ:ACHVGet Rating) last released its earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.07. During the same period in the prior year, the company earned ($0.76) EPS. As a group, sell-side analysts predict that Achieve Life Sciences will post -2.13 earnings per share for the current year.

Institutional Trading of Achieve Life Sciences

Large investors have recently modified their holdings of the company. Prelude Capital Management LLC purchased a new stake in shares of Achieve Life Sciences in the 2nd quarter worth approximately $49,000. Charles Schwab Investment Management Inc. purchased a new stake in Achieve Life Sciences during the first quarter worth $79,000. HRT Financial LP bought a new stake in Achieve Life Sciences during the 4th quarter valued at $32,000. Raymond James & Associates bought a new stake in Achieve Life Sciences during the 1st quarter valued at $99,000. Finally, Morgan Stanley raised its position in shares of Achieve Life Sciences by 437.4% in the 4th quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 11,026 shares in the last quarter. Hedge funds and other institutional investors own 21.11% of the company’s stock.

Achieve Life Sciences Company Profile

(Get Rating)

Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

See Also

Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with’s FREE daily email newsletter.